[go: up one dir, main page]

GB202400470D0 - Agent delivery to the retina - Google Patents

Agent delivery to the retina

Info

Publication number
GB202400470D0
GB202400470D0 GBGB2400470.7A GB202400470A GB202400470D0 GB 202400470 D0 GB202400470 D0 GB 202400470D0 GB 202400470 A GB202400470 A GB 202400470A GB 202400470 D0 GB202400470 D0 GB 202400470D0
Authority
GB
United Kingdom
Prior art keywords
retina
agent delivery
delivery
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2400470.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB2400470.7A priority Critical patent/GB202400470D0/en
Publication of GB202400470D0 publication Critical patent/GB202400470D0/en
Priority to PCT/EP2025/050589 priority patent/WO2025149645A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2400470.7A 2024-01-12 2024-01-12 Agent delivery to the retina Ceased GB202400470D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2400470.7A GB202400470D0 (en) 2024-01-12 2024-01-12 Agent delivery to the retina
PCT/EP2025/050589 WO2025149645A1 (en) 2024-01-12 2025-01-10 Agent delivery to the retina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2400470.7A GB202400470D0 (en) 2024-01-12 2024-01-12 Agent delivery to the retina

Publications (1)

Publication Number Publication Date
GB202400470D0 true GB202400470D0 (en) 2024-02-28

Family

ID=89984202

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2400470.7A Ceased GB202400470D0 (en) 2024-01-12 2024-01-12 Agent delivery to the retina

Country Status (2)

Country Link
GB (1) GB202400470D0 (en)
WO (1) WO2025149645A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084319A1 (en) 2018-10-26 2020-04-30 Oxford University Innovation Limited Gene therapy
WO2020084318A1 (en) 2018-10-26 2020-04-30 Oxford University Innovation Limited Gene therapy for retinal disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084319A1 (en) 2018-10-26 2020-04-30 Oxford University Innovation Limited Gene therapy
WO2020084318A1 (en) 2018-10-26 2020-04-30 Oxford University Innovation Limited Gene therapy for retinal disease

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 2000, LIPPINCOTT, WILLIAMS & WILKINS
ALTSCHUL S. F., J MOL EVOL, vol. 36, 1993, pages 290 - 300
ALTSCHUL, S, F ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10
BOYE, HUM GENE THER, vol. 27, no. 8, 2016, pages 580 - 597
CEHAJIC-KAPETANOVIC ET AL., CURR BIOL, vol. 25, no. 16, 2015, pages 2111 - 2122
CEHAJIC-KAPETANOVIC ET AL., MOL THER METH CLIN DEV, vol. 9, 2017, pages 192 - 202
CEHAJIC-KAPETANOVIC ET AL., NAT MED, vol. 26, no. 3, 2020, pages 354 - 359
CHOI ET AL., CURR GENE THER, vol. 5, no. 3, 2005, pages 299 - 310
COURANARDI, VIROLOGY JOURNAL, vol. 4, 2007, pages 99
CUKRAS ET AL., MOL THER, vol. 26, 2018, pages 2282 - 2294
DALKARA ET AL., SCI TRANSL MED, vol. 5, 2013, pages 189 - 176
DALKARA ET AL., SCI TRANSLMED, vol. 5, 2013, pages 189 - 176
DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395
GUY ET AL., OPHTH, vol. 124, 2017, pages 1621 - 1634
KOCK, NUCLEIC ACIDS RESEARCH, 2015
KOTTERMAN ET AL., GENE THER, vol. 22, no. 2, 2015, pages 116 - 26
LAUGHLIN ET AL., PNAS, vol. 76, 1979, pages 5567 - 5571
MCCLEMENTS ET AL., J.BIOMEDRES INT., vol. 2021, 9 February 2021 (2021-02-09), pages 1 - 8
RUSSELL ET AL., LANCET, vol. 390, 2017, pages 849 - 860
SEOW ET AL., RNA, vol. 18, 2012, pages 1328 - 1337
VIGNAL ET AL., OPHTH, vol. 125, 2018, pages 945 - 947
WU ET AL., MOLECULAR THERAPY, vol. 14, no. 3, 2006, pages 316 - 327
YIN ET AL., INVEST OPHTH VIS SCI, vol. 52, 2011, pages 2775 - 2783

Also Published As

Publication number Publication date
WO2025149645A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
MX2010013766A (en) Rasagiline for parkinson's disease modification.
MX369385B (en) Products for healing of tissue wounds.
GB201915519D0 (en) Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MY194870A (en) Stuffy nose deblocking composition having antiviral activity
MX348531B (en) Dual spray can topical delivery device.
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2013022243A3 (en) Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient
RU2018109412A (en) HYDROPHILIC GEL FOR LOCAL DELIVERY OF 5-AMINOLEVULINIC ACID
PH12013500371A1 (en) Therapeutic agent for pain
CA3264923A1 (en) Composition for use in the treatment of fabry disease
GB202400470D0 (en) Agent delivery to the retina
NZ710583A (en) Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals
MX2020005809A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye.
GB202201139D0 (en) Therapeutic agent
MY163107A (en) Pharmaceutical composition for the treatment of bladder disorders
WO2012020021A9 (en) Glycyrrhetinic acid amine analogues for use in the treatment of inflammation, infectious diseases, cancer, autoimmune diseases, skin diseases, bone diseases and metabolic diseases
GB202418855D0 (en) Medicament
GB202418897D0 (en) Medicament

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)